SOVUNA

Peak

hydroxychloroquine sulfate

NDAORALTABLET
Approved
Jan 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2

Clinical Trials (2)

NCT01551069Phase 3Completed

Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion

Started Mar 2012
103 enrolled
Cutaneous Lupus Erythematosus-Systemic Lupus Erythematosus
NCT00946790Phase 1Completed

To Demonstrate the Relative Bioavailability of Hydroxychloroquine Sulfate, 200 mg Tablets

Started Jul 1993
72 enrolled
ImmunosuppressionRheumatism
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers